IperionX shares (ASX: IPX) crashed 14.29% to close at A$6.12 on Thursday, making the titanium developer the worst performer on the ASX 200 as markets digested a sharply widened half-year loss that underscored the company’s intensifying cash burn ahead of planned commercial production.
The sell-off marks a dramatic reversal for IperionX shares, which had rallied 23% on the month leading in to the print, on optimism surrounding the company’s US government-backed titanium manufacturing expansion and progress on its Tennessee minerals project. Thursday’s decline wiped out a large portion of those gains, with the IPX share price now 5.7% higher YTD.
Losses Drive The Move Lower in IPX
IperionX reported a net loss of US$34.8 million for the six months ended 31 December 2025, more than double the US$16.2 million loss recorded in the prior corresponding period. The deterioration was driven by a broad-based increase in spending across research and development, exploration, and corporate functions as the company accelerates its push to establish commercial-scale titanium production in the United States.
Research and development expenses reached approximately US$10.8 million during the half, reflecting ongoing work on IperionX’s proprietary titanium manufacturing processes at its Virginia campus. The company is developing technology aimed at producing low-cost, low-carbon titanium metal using recycled scrap titanium and domestically sourced minerals, positioning itself as a potential alternative to traditional production methods and Chinese-dominated supply chains.
Exploration and evaluation costs rose to US$3.3 million, linked to advancement of the Titan Critical Minerals Project in Tennessee, which the company describes as hosting one of the largest US resources of titanium, zircon, and rare earth mineral sands. Corporate and administrative expenses climbed to roughly US$16.1 million as IperionX expanded its workforce and operational footprint to support its dual-listed structure and growing project pipeline.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Management characterised the elevated spending as a deliberate investment phase, with funds directed toward scaling the company’s titanium manufacturing capabilities and advancing key project milestones. During the period, IperionX continued ramping up activity at its Virginia titanium manufacturing campus, which is expected to significantly increase production in coming years. The company has outlined plans to expand production capacity to around 1,400 tonnes per year by 2027, a target that would represent a material step toward commercial-scale operations.
The company is also progressing a definitive feasibility study for the Titan Critical Minerals Project, with completion targeted for the second quarter of 2026. The project has received US$47.1 million in US government funding to support the DFS, part of more than US$60 million in total federal backing IperionX has secured since early 2023 across various programs. In August 2025, the company announced receipt of US$12.5 million from the US Department of Defense to accelerate titanium production expansion at its Virginia facility, with total DoD funding obligations for that project reaching US$17.5 million and a further US$29.6 million expected over the contract term.
The financial results reignite debate over IperionX’s valuation, which has been a point of contention since short-seller Spruce Point Capital released a critical report in November 2025. That report, which sent the stock plunging 24% intraday, questioned whether the company’s technology would displace established titanium production methods and highlighted valuation multiples the short seller argued were excessive relative to sector peers and the company’s pre-revenue status.
IperionX responded at the time by emphasising its US government backing, permitting progress, and operational achievements at its Virginia campus. However, the latest half-year result provides fresh ammunition for sceptics who contend that the company’s valuation remains untethered from near-term financial fundamentals, particularly given the absence of meaningful revenue and the intensifying capital requirements ahead of the Titan project’s potential development.
What Comes Next?
Markets will now focus on IperionX’s ability to deliver on several critical milestones over the next 12 to 24 months. Completion of the Titan DFS in mid-2026 represents a key inflection point that could unlock project financing options and provide clarity on the economics of a potential mining operation. Demonstrable progress in scaling titanium production volumes and unit economics at the Virginia campus will be equally important in validating the company’s technology and commercial proposition.
The company’s funding position will remain under scrutiny, with the elevated cash burn rate raising questions about the timing and structure of future capital raises. While US government grants provide valuable non-dilutive support, the capital intensity of both the Virginia expansion and potential Titan mine development suggests additional funding will be required, likely through equity issuance, strategic partnerships, or project-level debt once the DFS is complete.
From a thematic perspective, IperionX remains well-positioned within the broader US push to secure domestic supply chains for critical minerals, particularly titanium, where China controls an estimated 65% of global production. The alignment with national security priorities and the company’s progress in securing federal funding provide a structural tailwind that continues to attract long-term institutional interest despite near-term volatility.
Thursday’s sharp sell-off reflects markets re-pricing the execution and financing risks inherent in IperionX’s aggressive growth strategy, tempering recent optimism with a dose of financial reality. While the company’s strategic positioning and government backing remain intact, the path from here will require flawless delivery on production scale-up, project development, and capital management to justify the premium valuation and restore market confidence.
